SOP for Division 5 CTA Submissions and Lifecycle Events (Health Canada)

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-division-5-cta-submissions-and-lifecycle-events-health-canada”
},
“headline”: “SOP for Division 5 CTA Submissions and Lifecycle Events (Health Canada)”,
“description”: “This SOP defines the procedures for preparing, submitting, and managing Clinical Trial Applications (CTAs) and lifecycle events under Division 5 of the Canadian Food and Drug Regulations. It ensures compliance with Health Canada requirements, covering initial submissions, amendments, notifications, and end-of-trial obligations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Published on 22/12/2025

Standard Operating Procedure for Division 5 CTA Submissions and Lifecycle Events (Health Canada)

SOP No.	CR/OPS/165/2025
Supersedes	NA
Page No.	X of Y
Issue Date	27/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Table of Contents

Purpose

The purpose of this SOP is to

establish procedures for preparing, submitting, and managing Clinical Trial Applications (CTAs) and related lifecycle events in Canada under Division 5 of the Food and Drug Regulations. It provides guidance for sponsors, CROs, and investigators to ensure compliance with Health Canada requirements, safeguard subject safety, and maintain regulatory transparency. This SOP addresses initial CTA submission, amendments, notifications, withdrawal, and end-of-trial reporting.

Scope

This SOP applies to sponsors, CROs, regulatory affairs professionals, investigators, data managers, QA personnel, and pharmacovigilance (PV) staff involved in clinical trial submissions in Canada. It covers trials for pharmaceuticals, biologics, radiopharmaceuticals, advanced therapies, and other investigational medicinal products regulated by Health Canada under Division 5. The SOP also outlines inspection readiness practices specific to Canadian requirements.

Responsibilities

Sponsor: Ensures accurate and timely submission of CTAs and lifecycle updates to Health Canada.
CRO: Assists in compilation, quality control, and submission of CTA documents.
Investigator: Provides site-specific documents, such as qualifications, consent forms, and REB approvals.
Regulatory Affairs: Coordinates CTA submissions, maintains submission logs, and communicates with Health Canada.
PV Department: Manages safety data and ensures timely submission of safety reports and amendments.
QA: Audits CTA documents and lifecycle event submissions for compliance.

Accountability

The Sponsor’s Head of Regulatory Affairs is accountable for ensuring that CTA submissions and lifecycle management activities comply with Health Canada Division 5 requirements and timelines.

Procedure

1. Initial CTA Preparation
1.1 Assemble core CTA package: protocol, Investigator’s Brochure (IB), Chemistry and Manufacturing Information (CMC), Informed Consent Forms (ICFs), and supporting appendices.
1.2 Ensure documents comply with Health Canada’s Guidance for Clinical Trial Sponsors.
1.3 Perform internal QA review prior to submission.
1.4 Log all documents in CTA Preparation Log (Annexure-1).

2. Submission to Health Canada
2.1 Submit CTA through the appropriate Health Canada channel (currently via electronic Common Technical Document, eCTD).
2.2 Acknowledge receipt of confirmation and CTA Control Number from Health Canada.
2.3 Document in CTA Submission Log (Annexure-2).

3. Review and Queries
3.1 Monitor Health Canada feedback during the 30-day review period.
3.2 Respond to Requests for Clarification (RFCs) within specified deadlines.
3.3 Maintain a CTA Query Response Log (Annexure-3).

4. CTA Amendments
4.1 Classify amendments as substantial or administrative.
4.2 Substantial amendments include changes to study design, patient population, or safety monitoring.
4.3 Submit amendments with revised documents to Health Canada.
4.4 Track approvals in Amendment Log (Annexure-4).

5. Notifications
5.1 Notify Health Canada of protocol deviations, urgent safety measures, or investigator changes within defined timelines.
5.2 Submit annual updates summarizing ongoing trial progress.
5.3 Record in Notification Log (Annexure-5).

6. End-of-Trial Reporting
6.1 Submit an End-of-Trial Notification within 30 days of study closure.
6.2 Provide Clinical Study Report (CSR) within 12 months.
6.3 Document submissions in End-of-Trial Log (Annexure-6).

7. Withdrawal of CTA
7.1 Sponsors may withdraw CTAs voluntarily.
7.2 Submit withdrawal request with justification to Health Canada.
7.3 Document in Withdrawal Log (Annexure-7).

8. Safety Reporting Obligations
8.1 Submit expedited reports for Serious Unexpected Adverse Drug Reactions (SUSARs).
8.2 Report annual Development Safety Update Reports (DSURs).
8.3 Record in Safety Reporting Log (Annexure-8).

9. Inspection Readiness
9.1 Maintain inspection-ready archives for CTA submissions.
9.2 Conduct mock inspections annually to verify compliance.
9.3 Record findings in Inspection Readiness Log (Annexure-9).

10. Archiving and Retention
10.1 Archive CTA documents securely for at least 25 years or as required by Health Canada.
10.2 Implement both paper and electronic archiving with validated systems.
10.3 Record in Archiving Log (Annexure-10).

Abbreviations

SOP: Standard Operating Procedure
CTA: Clinical Trial Application
REB: Research Ethics Board
QA: Quality Assurance
PV: Pharmacovigilance
DSUR: Development Safety Update Report
SUSAR: Suspected Unexpected Serious Adverse Reaction
CSR: Clinical Study Report
eCTD: electronic Common Technical Document
CMC: Chemistry and Manufacturing Information

Documents

CTA Preparation Log (Annexure-1)
CTA Submission Log (Annexure-2)
CTA Query Response Log (Annexure-3)
Amendment Log (Annexure-4)
Notification Log (Annexure-5)
End-of-Trial Log (Annexure-6)
Withdrawal Log (Annexure-7)
Safety Reporting Log (Annexure-8)
Inspection Readiness Log (Annexure-9)
Archiving Log (Annexure-10)

References

Version: 1.0

Approval Section

Prepared By	Ravi Kumar, Regulatory Affairs Specialist
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head Regulatory Affairs

Annexures

Annexure-1: CTA Preparation Log

Date	Document	Prepared By	Status
01/09/2025	Protocol	Reg Affairs	Complete

Annexure-2: CTA Submission Log

Date	CTA Control No.	Submitted By	Status
02/09/2025	HC-CTA-2025-01	Sponsor	Submitted

Annexure-3: CTA Query Response Log

Date	Query	Response	Submitted By	Status
05/09/2025	Safety Monitoring Plan	Revised and Submitted	Reg Affairs	Resolved

Annexure-4: Amendment Log

Date	Amendment Type	Protocol ID	Submitted By	Status
07/09/2025	Substantial	CTA-2025-01	Reg Affairs	Approved

Annexure-5: Notification Log

Date	Notification Type	Submitted By	Status
10/09/2025	Investigator Change	CRO	Accepted

Annexure-6: End-of-Trial Log

Date	Protocol ID	Report Type	Submitted By	Status
12/09/2025	CTA-2025-01	End-of-Trial Notification	Sponsor	Submitted

Annexure-7: Withdrawal Log

Date	Protocol ID	Reason	Submitted By	Status
15/09/2025	CTA-2025-02	Enrollment Challenges	Sponsor	Withdrawn

Annexure-8: Safety Reporting Log

Date	Report Type	Submitted To	By	Status
18/09/2025	SUSAR Report	Health Canada	PV Team	Submitted

Annexure-9: Inspection Readiness Log

Date	Activity	Performed By	Findings	Status
20/09/2025	Mock Inspection	QA	No major findings	Compliant

Annexure-10: Archiving Log

Date	Document	Archived By	Location	Status
25/09/2025	CTA Submission Package	Archivist	TMF	Archived

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
27/08/2025	00	Initial version	New SOP creation	Head Regulatory Affairs

For more SOPs visit: Pharma SOP